Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
Filter
  • American Society of Hematology  (2)
  • 1
    In: Blood, American Society of Hematology, Vol. 128, No. 22 ( 2016-12-02), p. 1230-1230
    Abstract: Introduction: Immune reconstitution after stem cell transplantation (SCT) plays a crucial role in host defense against microbial agents. The thymus atrophy occurring with ageing represents a limit for de novo T-cell reconstitution, although the reactivation of thymic function after BMT is documented. The proper strategy to improve the thymic output is currently matter of debate. Pre-clinical and clinical evidences suggest that Zinc oral supplementation may contribute to thymic reactivation and to improve the T-mediated cellular defense against pathogens. We tested the role of Zinc oral supplementation in immune reconstitution, using as model the autologous SCT in multiple myeloma. Methods: From January 2014 to May 2016, we prospectively enrolled 18 patients (12 male, 6 female; average age: 58 years, range 43-72) undergoing single MEL 100 or 200 auto-SCT after one or two lines of therapy (VTD, lyposomal anthracycline and lenalidomide) and stem cell collection (mobilizing therapy: cyclophosphamide 3 g/sqm and G-CSF). The trial, prospective and randomized, has been approved by local ethics committee (EUDRACT: 2014-004499-47). All patients undersigned the informed consent. The clinical trial was carried out in accordance with Helsinki declaration. Randomization was effected at day 0 (day of PBSC infusion). Results: nine patients were treated from day +5 to day +100 after transplant with 600 mg/day of Zinc sulfate (uncoated tablets), whereas nine patients received only standard antimicrobial prophylaxis. Peripheral blood samples were collected in both groups at day +30 (t2) and day +100 (t3). Eight-colour flow cytometry was performed for CD3, CD4, CD8, CD45RA, CD45R0, CD27, CD28, CD25, CD127, with specific gates to identify specific lymphocyte populations (T naïve, T central memory, T effector memory, T terminal memory). The lymphocyte's population's count was statistically analysed intra- and inter-group with Wilcoxon test. Droplet-digital PCR for TRECs was performed on lymphocytes isolated by peripheral blood. A qPCR for viral load of Torquetenovirus (TTV), a harmless virus whose viral load is related to immunodepression, was performed. Zinc serum level was measured. Results: The only significant difference in the clinical features between the 2 groups was the mean age (58 years in the control group, 63 years in the sample). The recovery of naïve CD4 cells was visible in both groups from day +30 to day +100, but a significant increase was detected only in the Zinc group. Similarly, TRECs showed a significant increase in the treated group. CD8+ T cells showed a notable decrease until day 100 in the control group, specifically the CD8 naïve, memory, and effector memory populations. TTV load in the control group increased in inverse proportion to the decrease of CD8 population. In the Zinc group there were no differences between the TTV loads at the two time points. As a result, the viral load of TTV was higher in the control group than in the Zinc group at day +100. Zinc serum levels were normal in all patients. Conclusions: data show that Zinc plays a role in a faster recovery of TRECs and CD4 naïve T cells after autologous transplantation. Furthermore, Zinc seems to prevent the expected CD8 decrease of the control group, thus probably explaining the TTV reactivation. Zinc-deficiency was not observed in any of the patient; however, a Zinc supplementation may contribute to a better T-cell reconstitution. To the best of our knowledge, this is the first study describing the role of Zinc after stem cell transplantation. Disclosures No relevant conflicts of interest to declare.
    Type of Medium: Online Resource
    ISSN: 0006-4971 , 1528-0020
    RVK:
    RVK:
    Language: English
    Publisher: American Society of Hematology
    Publication Date: 2016
    detail.hit.zdb_id: 1468538-3
    detail.hit.zdb_id: 80069-7
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 2
    In: Blood, American Society of Hematology, Vol. 124, No. 21 ( 2014-12-06), p. 5548-5548
    Abstract: Myeloproliferative neoplasms (MPNs) are a group of clonal diseases associated with JAK2 mutation (V617F) in a percentage varying from 50% (Essential Thrombocytemia ET, and Primary Myelofibrosis PMF) to 95% (Polycitemia Vera, PV). The standard method for determining the V617F mutation is today represented by the Real Time PCR (RT-PCR). However, in recent years some studies have focused attention on a new method, the Droplet Digital PCR (DD-PCR), that allows an absolute quantitation of the mutated allele without any reference curve. The main objective of this study was the comparison of two PCR methods (RT-PCR and DD-PCR) for the analysis of the JAK2V617F mutation in order to assess the sensitivity, specificity and feasibility of the two techniques. In the study 225 patients with MPNs JAK2V617F-positive were enrolled; in 99 cases, DNA was still available for further assays and so DD-PCR tests were performed and compared with the results coming from RT-PCR (MutaQuant kit, Ipsogen, Luminy Biotech, Marseille, France). The results show a good sensitivity for both methods; nevertheless, after appropriate dilution tests, the DD-PCR was able to detect the JAK2V617F mutation in the 5x10-4 dilution versus 5x10-3 for the RT-PCR, in front of a fully comparable specificity. A linear regression analysis showed an absolute correlation between the 2 methods (R2=0.91), and the median mutated allele burden was not different when measured by the DD-PCR or the RT-PCR (p=0.67), with the highest median allele burden observed in secondary myelofibrosis (86% by RT-PCR and 91% by DD-PCR) and the lowest one in ET (23% by RT-PCR and 25% by DD-PCR) (see Figure 1 and Figure 2), as expected. Figure 1 Figure 1. Figure 2 Figure 2. Our study demonstrates that a new molecular technique, the DD-PCR, may represent a new frontier in the world of molecular techniques for the detection of JAK2 mutation with a high sensitivity and specificity. In addition the method allows obtain two types of information, qualitative and quantitative, with one analysis, saving time and at a lower cost than the standard method. Disclosures No relevant conflicts of interest to declare.
    Type of Medium: Online Resource
    ISSN: 0006-4971 , 1528-0020
    RVK:
    RVK:
    Language: English
    Publisher: American Society of Hematology
    Publication Date: 2014
    detail.hit.zdb_id: 1468538-3
    detail.hit.zdb_id: 80069-7
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
Close ⊗
This website uses cookies and the analysis tool Matomo. Further information can be found on the KOBV privacy pages